REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/28/2025
Back to search
Official data from USPTO
IMMUNOSCAPE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
04/29/2025
Trademark type
Word
Nice classes
42
Filing date
07/12/2018
Registration date
04/28/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/28/2020
Last transaction
04/29/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
First use anywhere
2017-03-00
First use in commerce
2017-03-00
Drawing code
4
Owner type
99
Owner location
Singapore, SG
Examiner
HETZEL, DANNEAN
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
immunoscape Pte Ltd
Representatives
Jon Jekel Pillsbury Winthrop Shaw Pittman LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development services in the field of biotechnology; Research and development services in the field of immune profiling; research and development services in the field of immunotherapy; biotechnology servicesprobing for multiple T cell specificities identification of tumor antigen-specific T cells for the treatment of cancer; biotechnology servicesprobing for multiple T cell specificities identification of viral antigen-specific T cells in the field of infectious diseases; biotechnology servicesphenotypic and functional T cell and/or other immune cells profiling for use in the field of immunotherapy; biotechnology servicesanalysis by time-of-flight mass cytometry; research services in the field of biomarker discovery; clinical research services for determining a response to treatment for patient stratification via biomarkersdetermining the presence of biomarkers in patient samples; biotechnology servicescharacterization of biomarkersdevelopment and evaluation of biochemicalbiological or analytical assays to quantify biomarkers and surrogate markers for the identification of patients and the treatment efficacy or prevention of diseasesdisorders and conditions associated with the immune system; consulting services in the field of biotechnology through the application of mass cytometry; Research and development services in the field of vaccines; research and development of immunotherapy products; research and development of vaccines for use in the field of immunotherapy; research and development services in the field of vaccinesimmunotherapies for the treatment of infectious diseases and cancer; biotechnology servicesanalysis by flow cytometry; consulting services in the field of vaccine research and development in the field of immunotherapies; platform as a service (PAAS) featuring computer software platforms for accessingcollectingdetectingcomparingcalculatinganalyzingdisplayingtransmittingmanaging and storing immune profiling data; providing temporary use of online non-downloadable computer software for use in performing lab servicesdescribing the status of disease progressionprioritization of treatment strategies; providing temporary use of online non-downloadable computer software for use in data collectionreviewinterpretationcomparisonanalysis of T cells and/or other immune cells features; providing temporary use of on-line non-downloadable cloud computing software for accessingcollectingdetectingcomparingcalculatinganalyzingdisplayingtransmittingmanaging and storing immune profiling data; providing temporary use of on-line non-downloadable cloud computing software for use in performing lab servicesdescribing the status of disease progressionprioritization of treatment strategies; providing temporary use of on-line non-downloadable cloud computing software for use in data collectionreviewinterpretationcomparisonanalysis of T cells and/or other immune cells features
Publications
History of USPTO decisions and trademark events.
40 publications found
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
09/03/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/03/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/03/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/03/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/06/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/06/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/06/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
04/28/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/11/2020
PUBO
PUBLISHED FOR OPPOSITION
02/11/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/22/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/07/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/30/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/05/2019
GNSL
LETTER OF SUSPENSION E-MAILED
12/05/2019
CNSL
SUSPENSION LETTER WRITTEN
12/05/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/03/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
11/22/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/20/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/20/2019
CNSI
SUSPENSION INQUIRY WRITTEN
11/20/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
11/19/2019
ALIE
ASSIGNED TO LIE
11/12/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/19/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/18/2019
GNSL
LETTER OF SUSPENSION E-MAILED
04/18/2019
CNSL
SUSPENSION LETTER WRITTEN
04/18/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/16/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/15/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/15/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/08/2018
GNRT
NON-FINAL ACTION E-MAILED
11/08/2018
CNRT
NON-FINAL ACTION WRITTEN
11/08/2018
DOCK
ASSIGNED TO EXAMINER
10/30/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/17/2018
NWAP
NEW APPLICATION ENTERED
07/16/2018
Continuous trademark protection
Get notified about every new filing that threatens IMMUNOSCAPE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.